Cargando…

Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis

BACKGROUND: Detection of molecular tumor heterogeneity has become of paramount importance with the advent of targeted therapies. Analysis for detection should be comprehensive, timely and based on routinely available tumor samples. AIM: To evaluate the diagnostic potential of targeted multigene next...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mafficini, Andrea, Amato, Eliana, Fassan, Matteo, Simbolo, Michele, Antonello, Davide, Vicentini, Caterina, Scardoni, Maria, Bersani, Samantha, Gottardi, Marisa, Rusev, Borislav, Malpeli, Giorgio, Corbo, Vincenzo, Barbi, Stefano, Sikora, Katarzyna O., Lawlor, Rita T., Tortora, Giampaolo, Scarpa, Aldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134249/ https://www.ncbi.nlm.nih.gov/pubmed/25127237 http://dx.doi.org/10.1371/journal.pone.0104979

Ejemplares similares

DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples
por: Simbolo, Michele, et al.
Publicado: (2013)

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
por: Simbolo, Michele, et al.
Publicado: (2016)

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma
por: Simbolo, Michele, et al.
Publicado: (2018)

Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas
por: Amato, Eliana, et al.
Publicado: (2018)

Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine
por: Simbolo, Michele, et al.
Publicado: (2018)

RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes
por: Amato, Eliana, et al.
Publicado: (2016)

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
por: Simbolo, Michele, et al.
Publicado: (2014)

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
por: Mafficini, Andrea, et al.
Publicado: (2016)

Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel
por: Scarpa, Aldo, et al.
Publicado: (2013)

Chromosome 3p alterations in pancreatic endocrine neoplasia
por: Amato, Eliana, et al.
Publicado: (2010)

Next-generation sequencing for genetic testing of familial colorectal cancer syndromes
por: Simbolo, Michele, et al.
Publicado: (2015)

Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53
por: Malpeli, Giorgio, et al.
Publicado: (2017)

Long-term organoid culture of a small intestinal neuroendocrine tumor
por: D’Agosto, Sabrina, et al.
Publicado: (2023)

Exosomal miRNA signatures of pancreatic lesions
por: Vicentini, Caterina, et al.
Publicado: (2020)

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas
por: Amato, Eliana, et al.
Publicado: (2014)

Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
por: Corbo, Vincenzo, et al.
Publicado: (2012)

Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease
por: Filippini, Dea, et al.
Publicado: (2019)

Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
por: Vicentini, Caterina, et al.
Publicado: (2014)

pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells
por: Barresi, Valeria, et al.
Publicado: (2022)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Current role of non-coding RNAs in the clinical setting
por: Vicentini, Caterina, et al.
Publicado: (2019)

Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors
por: Malpeli, Giorgio, et al.
Publicado: (2011)

Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study
por: Nicosia, Luca, et al.
Publicado: (2020)

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
por: Luchini, Claudio, et al.
Publicado: (2021)

Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis
por: Bria, E., et al.
Publicado: (2016)

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
por: Carbognin, Luisa, et al.
Publicado: (2020)

Non-coding regulatory variations: the dark matter of pancreatic cancer genomics
por: Scarpa, Aldo, et al.
Publicado: (2018)

Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium
por: Mafficini, Andrea, et al.
Publicado: (2018)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling
por: Mafficini, Andrea, et al.
Publicado: (2021)

Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants
por: Mafficini, Andrea, et al.
Publicado: (2022)

The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome
por: Melchionna, Roberta, et al.
Publicado: (2016)

Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment
por: Barresi, Valeria, et al.
Publicado: (2019)

Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo
por: Lupo, Francesca, et al.
Publicado: (2020)

Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries
por: Corbo, V., et al.
Publicado: (2012)

IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation
por: Barresi, Valeria, et al.
Publicado: (2021)

Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas
por: Corbo, Vincenzo, et al.
Publicado: (2010)

Loss of FGFR4 promotes the malignant phenotype of PDAC
por: D’Agosto, Sabrina, et al.
Publicado: (2022)

Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
por: Sorio, Claudio, et al.
Publicado: (2011)

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
por: Gkountakos, Anastasios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4nscc028rbirsf25ipttf3rfgd